Different Ways To help Expand Integrase inhibitor Over A Tiny Spending Budget

Over the 12?years of follow-up mortality did not decline (adjusted test for trend: p=0.09). Three periods could be distinguished (Figure?1) �C a stable mortality in the beginning followed by an increase and then a decline. In the first 5?years, the mortality rate varied between 707 in 1996 and 775 per 100.000 PYO in 1998 (Table?1); In 2001, there was a sudden increase representing the highest HR for the whole 12?years period (1023 per 100,000 PYO). Mortality then declined slightly, but in this period, from 2001 to 2003, mortality increased 14% (HRR=1.14; 95% CI: 0.98-1.32; p=0.08) compared to the previous five years period. Integrase inhibitor drugs Then, from 2004 to 2007, a significant 25% decrease occurred (HRR=0.75; 95% CI: 0.64-0.87; pOxalosuccinic acid the period from 1996 to 2000 mortality was 27% higher (HRR=1.27; 95% CI: 1.09-1.46; p=0.001); from 2001 to 2003, mortality continued to increase (HRR=1.52; 95% CI: 1.30-1.78; p mortality was observed between 2001 and 2003 with rates of 1516, 1229 and 1427 per 100,000 PYO, respectively, and with another peak in 2005 (HR=1270 per 100,000 PYO). In the north - in Oio, Cacheu and Biombo - mortality increased slowly from 1996 (HR=583 per 100,000 PYO) attaining the peak in 2000 (HR=1134 per 100000 PYO) in Oio, and then a steady decrease occurred until 2007 (HR=271 per 100,000 PYO). Figure 2 Trends in mortality of women of reproductive age by region, 1996�C2007. Hazard mortality rates per 100,000 person-years-at-risk by ABT-199 cost northern (Biombo, Cacheu and Oio) and eastern (Bafata and Gabu) regions are presented. In the unadjusted analysis, mortality was higher in the eastern regions, Bafata (HR=947 per 100,000 PYO) and Gabu (885 per 100,000 PYO), compared with the northern regions where the HR was 536 per 100,000 in Cacheu, 558 per 100,000 PYO in Biombo and 681 per 100,000 PYO in Oio. Compared with Cacheu, Bafata had 74% (p